Regeneron Pharmaceuticals, Inc. (REGN)
| Previous close | 823.32 |
| Open | 817.81 |
| Bid | 821.31 x 800 |
| Ask | 822.63 x 1000 |
| Day's range | 809.24 - 823.08 |
| 52-week range | 668.00 - 853.97 |
| Volume | |
| Avg. volume | 451,079 |
| Market cap | 89.429B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 23.40 |
| EPS (TTM) | 35.08 |
| Earnings date | 01 Feb 2024 - 05 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 920.09 |
ZacksEyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
Insider MonkeyJP Morgan’s Top 15 Stock Picks for 2023 and Now
In this piece, we will take a look at JP Morgan’s top 15 stock picks for 2023 and most recent stock picks. If you want to skip our introduction to the world’s biggest bank in terms of assets, its latest performance, and other details, then check out JP Morgan’s Top 5 Stock Picks for 2023. […]
GlobeNewswireRegeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET. This investor call follows Regeneron data updates presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, from December 9-12, 2023. The webcast may be accessed from the "Investors & Media" page of Regeneron's w
